Harvard Medical School (HMS) is the graduate medical school of Harvard University, founded in 1782 and based in Boston, Massachusetts. The school is a major center for medical education and biomedical research, with strengths in chemical biology, medicinal chemistry, pharmacology, genomics, systems biology, and bioengineering—fields closely linked to drug discovery and development.
Through its extensive network of affiliated hospitals and research institutes—including Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center—HMS supports basic, translational, and clinical research spanning target identification to clinical trials. Faculty and trainees contribute to publications, patents, and technology transfer, and collaborate with academic and industry partners on therapeutics, diagnostics, and platform technologies. HMS also trains physicians and scientists through MD, PhD, and combined-degree programs, supplying talent to the life sciences and biopharmaceutical sectors.
None yet. When a new project in the record names Harvard Medical School as owner, partner or investor, it shows here.
Partners will create an integrated translational platform to quantify mechanisms, pathways and kinetics of nose-to-brain drug transport using in vitro, in vivo and computational tools.
FDA cleared therapy for wAIHA in patients ≥12 previously or currently treated with corticosteroids; showed rapid hemoglobin gains and durable responses in Phase 2/3 ENERGY.
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
Phase 3 trial shows KEYTRUDA and WELIREG improve disease-free survival in RCC. FDA accepts priority review for adjuvant treatment. Safety profile consistent with previous studies.
